Literature DB >> 31070797

Proteasomal Degradation of Enhancer of Zeste Homologue 2 in Cholangiocytes Promotes Biliary Fibrosis.

Nidhi Jalan-Sakrikar1,2, Thiago M De Assuncao1,2, Guang Shi1,2, Sayed Obaidullah Aseem1,2, Cheng Chi1,2, Vijay H Shah1,2,3, Robert C Huebert1,2,3.   

Abstract

During biliary disease, cholangiocytes become activated by various pathological stimuli, including transforming growth factor β (TGF-β). The result is an epigenetically regulated transcriptional program leading to a pro-fibrogenic microenvironment, activation of hepatic stellate cells (HSCs), and progression of biliary fibrosis. This study evaluated how TGF-β signaling intersects with epigenetic machinery in cholangiocytes to support fibrogenic gene transcription. We performed RNA sequencing in cholangiocytes with or without TGF-β. Ingenuity pathway analysis identified "HSC Activation" as the highly up-regulated pathway, including overexpression of fibronectin 1 (FN), connective tissue growth factor, and other genes. Bioinformatics identified enhancer of zeste homologue 2 (EZH2) as an epigenetic regulator of the cholangiocyte TGF-β response. EZH2 overexpression suppressed TGF-β-induced FN protein in vitro, suggesting FN as a direct target of EZH2-based repression. Chromatin immunoprecipitation assays identified an FN promoter element in which EZH2-mediated tri-methylation of lysine 27 on histone 3 is diminished by TGF-β. TGF-β also caused a 50% reduction in EZH2 protein levels. Proteasome inhibition rescued EZH2 protein and led to reduced FN production. Immunoprecipitation followed by mass spectrometry identified ubiquitin protein ligase E3 component N-recognin 4 in complex with EZH2, which was validated by western blotting in vitro. Ubiquitin mutation studies suggested K63-based ubiquitin linkage and chain elongation on EZH2 in response to TGF-β. A deletion mutant of EZH2, lacking its N-terminal domain, abrogates both TGF-β-stimulated EZH2 degradation and FN release. In vivo, cholangiocyte-selective knockout of EZH2 exacerbates bile duct ligation-induced fibrosis whereas MDR2-/- mice are protected from fibrosis by the proteasome inhibitor bortezomib.
Conclusion: TGF-β regulates proteasomal degradation of EZH2 through N-terminal, K63-linked ubiquitination in cholangiocytes and activates transcription of a fibrogenic gene program that supports biliary fibrosis.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31070797      PMCID: PMC6819212          DOI: 10.1002/hep.30706

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  50 in total

1.  Structural basis of EZH2 recognition by EED.

Authors:  Zhifu Han; Xinmiao Xing; Min Hu; Yin Zhang; Peiyuan Liu; Jijie Chai
Journal:  Structure       Date:  2007-10       Impact factor: 5.006

Review 2.  Emerging concepts in biliary repair and fibrosis.

Authors:  Luca Fabris; Carlo Spirli; Massimiliano Cadamuro; Romina Fiorotto; Mario Strazzabosco
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-05-19       Impact factor: 4.052

Review 3.  Inner workings and regulatory inputs that control Polycomb repressive complex 2.

Authors:  M Maggie O'Meara; Jeffrey A Simon
Journal:  Chromosoma       Date:  2012-02-19       Impact factor: 4.316

4.  SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.

Authors:  W Lu; S Liu; B Li; Y Xie; M G Izban; B R Ballard; S A Sathyanarayana; S E Adunyah; R J Matusik; Z Chen
Journal:  Oncogene       Date:  2016-11-21       Impact factor: 9.867

Review 5.  Epithelial-mesenchymal interactions in biliary diseases.

Authors:  Luca Fabris; Mario Strazzabosco
Journal:  Semin Liver Dis       Date:  2011-02-22       Impact factor: 6.115

6.  Development and characterization of human-induced pluripotent stem cell-derived cholangiocytes.

Authors:  Thiago M De Assuncao; Yan Sun; Nidhi Jalan-Sakrikar; Mary C Drinane; Bing Q Huang; Ying Li; Jaime I Davila; Ruisi Wang; Steven P O'Hara; Gwen A Lomberk; Raul A Urrutia; Yasuhiro Ikeda; Robert C Huebert
Journal:  Lab Invest       Date:  2015-04-13       Impact factor: 5.662

7.  EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma.

Authors:  Haiou Liu; Yidong Liu; Weisi Liu; Weijuan Zhang; Jiejie Xu
Journal:  Nat Commun       Date:  2015-09-25       Impact factor: 14.919

8.  Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression.

Authors:  Adrienne Grzenda; Gwen Lomberk; Phyllis Svingen; Angela Mathison; Ezequiel Calvo; Juan Iovanna; Yuning Xiong; William Faubion; Raul Urrutia
Journal:  Epigenetics Chromatin       Date:  2013-02-28       Impact factor: 4.954

9.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.

Authors:  Edward Y Chen; Christopher M Tan; Yan Kou; Qiaonan Duan; Zichen Wang; Gabriela Vaz Meirelles; Neil R Clark; Avi Ma'ayan
Journal:  BMC Bioinformatics       Date:  2013-04-15       Impact factor: 3.169

10.  Fibronectin expression is critical for liver fibrogenesis in vivo and in vitro.

Authors:  Xiao-Ya Liu; Rui-Xia Liu; Fei Hou; Li-Jian Cui; Chun-Yun Li; Cheng Chi; Entong Yi; Yan Wen; Cheng-Hong Yin
Journal:  Mol Med Rep       Date:  2016-08-25       Impact factor: 2.952

View more
  6 in total

1.  Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300/ELK1 complex.

Authors:  Amaia Navarro-Corcuera; Tejasav S Sehrawat; Nidhi Jalan-Sakrikar; Hunter R Gibbons; Nicholas E Pirius; Shalil Khanal; Feda H Hamdan; Sayed Obaidullah Aseem; Sheng Cao; Jesus M Banales; Ningling Kang; William A Faubion; Nicholas F LaRusso; Vijay H Shah; Robert C Huebert
Journal:  J Hepatol       Date:  2021-12-23       Impact factor: 25.083

2.  Induced Pluripotent Stem Cells From Subjects With Primary Sclerosing Cholangitis Develop a Senescence Phenotype Following Biliary Differentiation.

Authors:  Nidhi Jalan-Sakrikar; Thiago M De Assuncao; Amaia Navarro-Corcuera; Feda H Hamdan; Lorena Loarca; Lindsey A Kirkeby; Zachary T Resch; Steven P O'Hara; Brian D Juran; Konstantinos N Lazaridis; Charles B Rosen; Julie K Heimbach; Timucin Taner; Vijay H Shah; Nicholas F LaRusso; Robert C Huebert
Journal:  Hepatol Commun       Date:  2021-08-25

Review 3.  ER Disposal Pathways in Chronic Liver Disease: Protective, Pathogenic, and Potential Therapeutic Targets.

Authors:  Caroline C Duwaerts; Jessica L Maiers
Journal:  Front Mol Biosci       Date:  2022-01-31

4.  Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor-β Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis.

Authors:  Sayed Obaidullah Aseem; Nidhi Jalan-Sakrikar; Cheng Chi; Amaia Navarro-Corcuera; Thiago M De Assuncao; Feda H Hamdan; Shiraj Chowdhury; Jesus M Banales; Steven A Johnsen; Vijay H Shah; Robert C Huebert
Journal:  Gastroenterology       Date:  2020-10-12       Impact factor: 22.682

5.  Epigenetic silencing of LncRNA ANRIL enhances liver fibrosis and HSC activation through activating AMPK pathway.

Authors:  Jing-Jing Yang; Yang Yang; Chong Zhang; Jun Li; Yan Yang
Journal:  J Cell Mol Med       Date:  2020-01-20       Impact factor: 5.310

6.  Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer.

Authors:  Yan Sun; Dianyun Ren; Yingke Zhou; Jian Shen; Heshui Wu; Xin Jin
Journal:  Cell Death Dis       Date:  2021-09-25       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.